Business Wire - March 28, 2005

Energex's experimental treatment involves exposing a very small amount of an infected subjects blood (3-4%) to a very precise amount of ultra-violet light in the C band (UVC), for a very precise amount of time, explained Thomas Petrie, the developer of the technology and Director of Engineering at Energex Systems. "After exposure the treated blood is returned to the patient through the same portal it was drawn from. The result, we believe, is a stimulation of the immune system", said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran with a viral load of at least 100,000 IU or more were administered PCR tests before treatment, on days 1,8, and 15. The average of the tests is the baseline that post-treatment tests are compared to. After the blood draw on day 15, the 1st treatment is administered, followed by the 2nd treatment on day 17. Prior to the 3rd treatment on day 20, the first post-treatment PCR test is administered and the result is compared to the baseline. The 4th and 5th treatments are administered on days 25 and 30 respectively. On day 33 the 1st PCR test after the last treatment is administered and compared to the baseline. Additional PCR tests are administered on days 57, 64 and 71 and the average of the tests is compared to the baseline.

As an example of the effectiveness of the therapy as established in the trial, the Company reported that three subjects (3 of 10) had sustained viral load reductions of 90% or greater at 10 weeks post treatment and eight had sustained reductions of 50% or greater. Only two subjects did not respond to the therapy.

"We are encouraged by the results of this trial, particularly, the rapid and dramatic viral load reductions we saw and the fact that there were no reported adverse events related to the therapy", said Thomas J. Fagan, President of Energex Systems. Hepatitis C is just the beginning. Preliminary laboratory work we have done on SIV/HIV/AIDS suggests that this therapy will be effective in treating those viruses. It is our intention to seek approval from the Federal Food and Drug Administration (FDA) through an Investigation Device Exemption (IDE) to conduct a trial on humans inflicted with HIV/AIDS. We are excited about the potential that our technology has to manage these hard-to-treat diseases, to reduce the cost of care, and to provide a better quality of life for the millions that suffer from them. We are committed to expending whatever resources are necessary to see that this technology continues through the research and approval processes, and that it is accepted by the medical community as the treatment of choice for these potentially life threatening diseases," said Fagan.

Energex Systems is dedicated to developing medical technologies and therapies with an emphasis on the treatment of conditions unmet by present day therapies and reducing the cost of care.

CONTACT: Energex Systems, Inc.

Thomas J. Fagan, 201-261-0099 ext.11

Fax: 201-261-8939

tfagan@energexsystems.com

SOURCE: Energex Systems, Inc.

050328
BW050318

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .